Nicox: 2022 Ordinary General Meeting of Shareholders

press release Nicox: 2022 Ordinary General Meeting of Shareholders

May 4, 2022 – Broadcast at 7:30 am
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX, Qualified PEA-PME), an international company specializing in ophthalmology invites shareholders to an annual shareholders meeting Tuesday, June 14, 2022 2:00 pmBuroClub – Drakkar 2 – Building D – 2405 route des Dolines – 06560 Valbonne Located in the office of Sophia Antipolis.

The information contained in Articles R.22-10-23 of the Commercial Code, including voting rights exercises, will be sent to shareholders in response to a simple written request. These documents will be made available to shareholders by May 24, 2022 at our registered office and its website (www.nicox.com).

Shareholders may exercise their voting rights by proxy, exercise their voting rights online, or attend a general meeting of shareholders. A guide explaining how to exercise your voting rights, especially via the Internet, will be posted on our website by May 24, 2022. Questions about the voting process.

If the quorum required for General Assembly deliberation is not reached on the first phone call, a second meeting on the same agenda will be held at the BuroClub – Drakkar 2 Building D office on Tuesday, June 28, at 2:00 pm. – 2405 Route de Dorine – 06560 Valbonne Sophia Antipolis.

About Nicox Nicox SA is an international company specializing in ophthalmology that develops innovative solutions aimed at maintaining vision and improving eye health. Our main program in clinical development is NCX470, a new second-generation nitric oxide-donating bimatoprost analog for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nikox is also developing NCX4251, a patented formulation of fluticasone for dry eye. Nicox is making money from VYZULTA® For glaucoma, it is exclusively licensed to Bausch + Lomb and ZERVIATE worldwide.® With allergic conjunctivitis. ZERVIATE is licensed in several regions, including Eyevance Pharmaceuticals for the US, LLC and Ocumension Therapeutics for most of the Chinese and Southeast Asian markets.

Headquartered in Sophia Antipolis (France), Nicox is listed on Euronext Paris (Compartment C: Midcap, Ticker: COX) and is part of the CAC Healthcare, CAC Pharma & Bio, Next 150 Index.

For more information on Nicox, its products, or its portfolio, please visit http://www.nicox.com.

Analyst coverage

Bryan, Garnier & Co Victor Floc’h Paris, France
Edison Investment Research Pooya Hemami London, UK
HC Wainwright & Co Yi Chen New York, USA
Kepler Cheuvreux Arsene Guekam Paris, France

The positions expressed by analysts in the notes regarding Nicox are their own and do not reflect our position. In addition, the information contained in their reports may be incorrect or out of date. Nikox undertakes no obligation to modify or update the information contained in the Analyst Report. contact address

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Corporate Development Manager
T +33 (0) 4 97 24 53 00
[email protected]

Investor Information and Media
America and Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78680 05 38
[email protected]

warning The information contained in this document is subject to change without notice. This information contains forward-looking statements that do not guarantee future performance. These statements are based on the current expectations and beliefs of Nikox SA’s management, and many factors and uncertainties that may cause actual results to differ materially from those stated in the forward-looking statements. Is affected by. Nicox SA and its affiliates, directors, officers, employees, advisors or agents undertake no obligation to update or revise any forward-looking statement.

Risk factors that may have a significant impact on Nicox SA’s business are described in Chapter 3 of the 2021 Universal Registration Document, Annual Report and Management Report filed with AMF on April 29, 2022. It has been and is available on Nicox. Website (www.nicox.com).

Nicox SA
Longship 2
Building D, 2405 Route Dedrine
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0) 4 97 24 53 00
F +33 (0) 4 97 24 53 99